Pfizer Corporation

Yong Tao

Ming Kang

Robert Wayne Dugger

Robert James Chambers

John Wing Wong

Michael Aaron Brodney

Christopher John Helal

Zheng Jane Li

Peter Robert Rose

Jeffrey W Raggon

Stephane Caron

Douglas James Critcher

Zhengong Bryan Li

Kevin Paul Girard

David Sydney Bernard Daniels

Nga M Do

Gregory Scott Goeken

Brian Matthew Samas

The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharma-ceutical composition containing the same, as well as preparations and uses thereof.

Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto

The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula I wherein Ris a group of the formula Gor Gdepicted below, wherein R, R, R, RX, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT) receptors, specifically, of one or both of the 5-HTand 5-HTreceptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HTagonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.

Benzyl(idene)-lactam derivatives

The present invention relates to novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine to pharmaceutical compositions containing such crystal forms and to methods of treatment. 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is a potent inhibitor of MAP kinases, preferably p38 kinase (MAPK14/CSBP/RK kinase). 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine

The present invention provides processes useful in the preparation of certain &#x3b2;-adrenergic receptor agonists of the structural formulathe pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.

Processes and intermediates useful in preparing &#x3b2;3-adrenergic receptor agonists

Processes and intermediates useful in preparing &bgr;3-adrenergic receptor agonists

Growing community of inventors

Salem, CT, United States of America

Yong Tao